Parkinson's drug repurposed to fight kidney disease?

NCT ID NCT06291116

Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a rotigotine skin patch, a drug used for Parkinson's disease, is safe for people with autosomal dominant polycystic kidney disease (ADPKD). ADPKD causes fluid-filled cysts in the kidneys and can lead to kidney failure. The trial will give 120 adults either standard care plus the rotigotine patch or standard care alone for 24 months, monitoring side effects and early signs of kidney protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: rotigotine (a dopamine agonist given as a skin patch)
What this could lead to: If it works, this could point toward a new way to slow kidney function loss and heart problems in people with ADPKD.
What could go wrong: This is an early Phase 2 safety study with only 120 people. It may not show clear benefit, and side effects like skin reactions or behavior changes are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ADPKD patients aged 18 to 60 years * Normotensive or hypertensive patients treated controlled (SBP/DBP on daytime ABPM \<135/85 mmHg less than 3 months old) * Patient having read and understood the information letter and signed the consent form * Effective contraception in women of childbearing age (for postmenopausal women, a confirmatory diagnosis should be obtained) * Patient benefiting from a social protection scheme Exclusion Criteria: * Stage 4 or 5 renal insufficiency (GFR CKD-EPI \<30 ml/min) * Renal transplant patients * Dialysis patients * History of myocardial infarction or stroke less than 6 months old * Severe hepatic insufficiency (Child-Pugh class C) * Patients currently being treated or treated in the 6 months preceding the trial with a dopamine agonist or antagonist * Systolic heart failure requiring hospitalization in the 6 months preceding inclusion or known heart failure with an LVEF \<30% * Orthostatic hypotension (decrease \> 20 mm Hg) * Pregnant, breastfeeding woman, or proven absence of contraception * Excessive alcohol consumption (greater than 20 g/day) * History of addictive behavior, particularly gambling, compulsive purchasing or hypersexuality * Drug addiction or suspected illicit drug use * Taking other sedative medications or other central nervous system depressants (benzodiazepines, antipsychotics, antidepressants or neuroleptics with antiemetic intent) * Hypersensitivity to the active ingredient, rotigotine, or to one of its excipients * Known allergy to sulphites * Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection, or guardianship or curatorship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autosomal dominant polycystic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

4 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Parkinson's drug repurposed to fight kidney disease?

What the study statuses mean